Show simple item record

dc.contributor.authorMontilla López, Alejandro
dc.contributor.authorMata, Gilda Paloma
dc.contributor.authorMatute Almau, Carlos José
dc.contributor.authorDomercq García, María
dc.date.accessioned2020-09-04T08:19:03Z
dc.date.available2020-09-04T08:19:03Z
dc.date.issued2020-08-03
dc.identifier.citationInternational Journal of Molecular Sciences 21(15) : (2020) // Articvle ID 5562es_ES
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10810/45984
dc.description.abstractThe release and extracellular action of ATP are a widespread mechanism for cell-to-cell communication in living organisms through activation of P2X and P2Y receptors expressed at the cell surface of most tissues, including the nervous system. Among ionototropic receptors, P2X4 receptors have emerged in the last decade as a potential target for CNS disorders such as epilepsy, ischemia, chronic pain, anxiety, multiple sclerosis and neurodegenerative diseases. However, the role of P2X4 receptor in each pathology ranges from beneficial to detrimental, although the mechanisms are still mostly unknown. P2X4 is expressed at low levels in CNS cells including neurons and glial cells. In normal conditions, P2X4 activation contributes to synaptic transmission and synaptic plasticity. Importantly, one of the genes present in the transcriptional program of myeloid cell activation is P2X4. Microglial P2X4 upregulation, the P2X4+ state of microglia, seems to be common in most acute and chronic neurodegenerative diseases associated with inflammation. In this review, we summarize knowledge about the role of P2X4 receptors in the CNS physiology and discuss potential pitfalls and open questions about the therapeutic potential of blocking or potentiation of P2X4 for different pathologies.es_ES
dc.description.sponsorshipThe authors work are supported by grants from Merck Serono (a business of Merck KGaA, Darmstadt, Germany), Spanish Ministry of Education and Science (SAF2016-75292-R and PID2019-109724RB-I00), Basque Government (IT1203/19 and PI-2016-1-0016) and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectpurinergic P2X4 receptores_ES
dc.subjectmicrogliaes_ES
dc.subjectneurones_ES
dc.subjectinflammationes_ES
dc.subjectCNS diseasees_ES
dc.titleContribution of P2X4 Receptors to CNS Function and Pathophysiologyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2020-08-07T13:38:01Z
dc.rights.holder2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/21/15/5562es_ES
dc.identifier.doi10.3390/ijms21155562
dc.departamentoesNeurociencias
dc.departamentoeuNeurozientziak


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).